Osteoporosis and the Growth Hormone-Insulin-Like Growth Factor Axis

Osteoporosis is the result of an imbalance between bone resorption and bone formation. Currently, mainly drugs that inhibit bone resorption are available for the treatment of osteoporosis. A new approach in the treatment of osteoporosis is the use of anabolic agents that increase bone turnover, both...

Full description

Saved in:
Bibliographic Details
Published inHormone research Vol. 58; no. Suppl 3; pp. 49 - 55
Main Authors Geusens, Piet P.M.M, Boonen, Steven
Format Journal Article
LanguageEnglish
Published Basel, Switzerland 01.01.2002
Subjects
Adult
Aging - physiology
Animals
Bone Diseases - etiology
Child
Growth Hormone - adverse effects
Growth Hormone - therapeutic use
Human Growth Hormone - deficiency
Human Growth Hormone - physiology
Humans
Insulin-Like Growth Factor I - adverse effects
Insulin-Like Growth Factor I - therapeutic use
Muscle
Osteoporosis - drug therapy
Osteoporosis - physiopathology
Somatomedins - physiology
Osteoporosis
Hip fracture
Insulin-like growth factor
Growth hormone
Online AccessGet full text

Cover

More Information
Summary:Osteoporosis is the result of an imbalance between bone resorption and bone formation. Currently, mainly drugs that inhibit bone resorption are available for the treatment of osteoporosis. A new approach in the treatment of osteoporosis is the use of anabolic agents that increase bone turnover, both bone formation and resorption. Growth hormone (GH) and insulin-like growth factors (IGFs) are essential in the development and growth of the skeleton and for the maintenance of bone mass and density. We will review the evidence of GH and IGF-I in the pathophysiology and treatment of osteoporosis.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISBN:9783805575232
3805575238
ISSN:1663-2818
0301-0163
1663-2826
DOI:10.1159/000066483